Table 1.
Anti-angiogenesis RNAi for revealing functions of cytokines and receptors
| Cytokines and receptors | Cells | RNAi agent | RNAi phenotype |
|---|---|---|---|
| VEGF | HeLa, MM66, ovarian carcinoma primary and immortalized human podocytes | SiRNA and vector-based siRNA | Knockdown of VEGF did not affect tumor cell proliferation [8]. |
| Reduction of VEGF by siRNA against VEGF165b[9] | |||
| EGFR (erbB1) | A431 | SiRNA | Inhibited EGF-induced tyrosine phosphorylation and induced cell apoptosis [38] |
| Her-2/neu | SK-OV-3, BT-474, MDA-MB-453 | Retroviral vector based | Slower proliferation, increased apoptosis, increased G0–G1 arrest [39] |
| VEGF R1/R2 | SVR (CRL-2280), 293 | SiRNA | Downregulation of endogenous mVEGFR1 in SVR cells and co-transfected mVEGFR2 in 293 cells [14] |
| Amphiregulin (AR) | SCC-9 | SiRNA | Inhibited cell proliferation, migration and activation of survival mediator Akt/PKB [43] |
| Mcl-1 | MEFs | SiRNA | Reduced FBS-, VEGF- and IL-6-induced proliferation, induced apoptosis [46] |
| SPK-1/SPK2 | T24 | SiRNA | SPK-1 siRNA, but not SPK-2 siRNA, blocks VEGF-induced accumulation of Ras-GTP and phospho-ERK [44] |
| PRB (progesterone receptor B) | T47-Dco | SiRNA | Abrogated estradiol induced VEGF expression [7] |